Bibliography
- PETERSON JT: Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. (2004) 9(1):63–79
- ••Up-to-date overview of the pitfalls ofMMP inhibitor development.
- MATTER H, SCHUDOK M: Recent advances in the design of matrix metalloproteinase inhibitors. Curr. Opin. Drug Discov. Devel (2004) 7(4):513–535.
- ••Timely review from Aventis that discussessome of the bicyclic sulfonamides, and related compounds from other companies, in more detail.
- DRUMMOND AH, BECKETT P, BROWN PD et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. (1999) 878:228–235.
- •Older review highlighting some of the pitfalls.
- COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295(5564):2387–2392.
- ••Good discussion of the problems withcompounds such as tanomastat.
- GUM RJ, HICKMAN D, FAGERLAND JA et al.: Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol (2001) 62(12):1661–1673.
- BROWN PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Investig Drugs (2000) 9(9):2167–2177
- SKOTNICKI JS, DIGRANDI MJ, LEVIN JI: Design strategies for the identification of MMP-13 and TACE inhibitors. Curr. Opin. Drug Discov. Devel (2003) 6(5):742–759.
- REITER L, ROBINSON RP, MCCLURE KF et al.: Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1 — SAP. and early clinical results. Inflam. Res. (2004) 53:3.
- BECKER DP, BARTA TE, BEDELL L et al.: a-Amino-B-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. (2001) 11(20):2719–2722.